ClinicalTrials.gg
Not yet recruitingNCT05914090Updated Oct 13, 2023

The Application of Enhanced Recovery After Surgery (ERAS) for Cardiovascular Surgery in Adult

An interventional study of ERAS in Cardiac Surgery and Enhanced Recovery After Surgery, sponsored by Yan Fuxia. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-13.

Sponsored by Yan Fuxia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,600
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Among adults, patients undergoing elective extracorporeal circulation for cardiac surgery are included in the ERAS strategy intervention plan, which mainly includes preoperative education, preoperative oral intake of multidimensional carbohydrate beverages, multimodal analgesia, blood protection strategies, correction of perioperative hypoalbuminemia, early removal of tracheal intubation, maintenance of blood sugar at reasonable levels, and targeted liquid therapy. The traditional plan group follows the current clinical diagnosis and treatment routine. By comparing the differences in the incidence of major postoperative outcomes (MACCE events, major pulmonary complications, and acute kidney injury) between the intervention group and the non intervention group, as well as comparing other adverse events (including but not limited to pneumonia, massive bleeding, postoperative arrhythmia, incision infection, postoperative nausea, vomiting, and delirium), all cause secondary intubation, and all cause secondary surgery between the two groups, and recording hospitalization time, ICU stay time The removal time of tracheal intubation and drainage tube, as well as the pain score during hospitalization and the total amount of opioid drug use (converted to equivalent dose morphine), hospitalization cost, postoperative recovery quality QoR15 scale score, and patient satisfaction score, were recorded to explore whether the ERAS regimen can reduce the incidence of major postoperative adverse events, improve patient prognosis, and accelerate postoperative recovery compared to traditional regimens.

02

Conditions studied

  • Cardiac Surgery
  • Enhanced Recovery After Surgery
03

In context

Lead sponsor

Yan Fuxia is the lead sponsor of 6 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 to 80 years
  • Patients awaiting elective cardiac surgery with cardiopulmonary bypass (CPB)

Exclusion criteria

Exclusion Criteria:

  • (ASA) class is above class V
  • Patients with cardiac assist device or mechanical ventilation
  • The of patients is less than 30%
  • Patients with morbid obesity
  • Patients with severe obstructive sleep apnea-hypopnea syndrome (OSAHS)
  • Patients with severe pulmonary disease, including severe (COPD) or respiratory failure
  • Patients with severe liver or renal dysfunction, including severe acute or chronic renal dysfunction need renal replacement therapy, and acute or chronic liver failure need artificial liver therapy
  • Patients with long-term opioid or sedative utilization
  • Patients with a history of alcohol or cigarette abuse
  • Patients with long-term hormone therapy
  • An > 2.0
  • Patients with severe malnutrition
  • Mental or legal disability
  • Current enrollment in another clinical trial
  • Patients' refusal or low adherence
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
3,600 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Procedure: ERAS

  • No intervention
    Control group

Interventions

  • ProcedureERAS

    Among adults, patients undergoing elective extracorporeal circulation for cardiac surgery are included in the ERAS strategy intervention plan, which mainly includes preoperative education, preoperative oral intake of multidimensional carbohydrate beverages, multimodal analgesia, blood protection strategies, correction of perioperative hypoalbuminemia, early removal of tracheal intubation, maintenance of blood sugar at reasonable levels, and targeted liquid therapy.

06

What researchers measure

Primary outcomes

  1. Composite outcomes

    The composite outcomes include the major adverse cardiac and cerebrovascular events (MACCE), major postoperative pulmonary complication (PPCs), and acute kidney injury (AKI).

    Time frame: during hospitalization, an average of 1 week, assessed up to 30 days

Secondary outcomes

  1. the quality of recovery score (QoR)-15 after surgery

    Time frame: At 24 hour after surgery

  2. length of hospital stay

    From the date of admission until the date of discharging

    Time frame: From the date of admission until the date of discharging, assessed up to 30 days

  3. the duration of intensive care unit (ICU) stay

    Time from ICU admission to ICU discharge

    Time frame: Time from ICU admission to ICU discharge, assessed up to 30 days

  4. time to extubation

    The time from the end of operation to the removal of tracheal intubation

    Time frame: The time from the end of operation to the removal of tracheal intubation, assessed up to 30 days

  5. time to drainage removal

    The time from the end of operation to the removal of drainage tube

    Time frame: The time from the end of operation to the removal of drainage tube, assessed up to 30 days

  6. the rate of other complications

    The rate of other complications include delium, pneumonia, pneumothorax, hematorrhea and so on

    Time frame: during hospitalization, an average of 1 week, assessed up to 30 days

  7. the rate of reintubation for any cause

    The rate of reintubation for any cause

    Time frame: during hospitalization, an average of 1 week, assessed up to 30 days

  8. cumulative opioid dosage

    Total perioperative consumption of opioid analgesics

    Time frame: during hospitalization, an average of 1 week, assessed up to 30 days

  9. overall medical costs

    Total cost of patients during hospitalization

    Time frame: during hospitalization, an average of 1 week, assessed up to 30 days

  10. satisfaction score

    A satisfaction rating using a 0-10 number scale (0=unsatisfactory, 10=satisfactory)

    Time frame: the day before discharge, assessed up to 30 days

  11. the outcomes of long-term prognosis by telephone follow-up

    the outcomes of prognosis

    Time frame: within 30 days, 3 months, and 1 year

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2023; primary completion for Jun 2024, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2023
First posted
Jun 22, 2023
StartEst.
Oct 11, 2023
Primary completionEst.
Jun 1, 2024
CompletionEst.
Dec 30, 2024
Last update
Oct 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05914090
Lead sponsor
Yan Fuxia
Responsible party
Yan Fuxia (principal investigator, Chinese Academy of Medical Sciences, Fuwai Hospital) — Sponsor-investigator
First posted
Jun 22, 2023
Start date
Oct 11, 2023 (estimated)
Primary completion
Jun 1, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Oct 13, 2023

Study contacts

Yan/Principle investigator
Contact
yanfuxia@sina.com
13641158173

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion